196 related articles for article (PubMed ID: 15944254)
21. The invariant chain inhibits presentation of endogenous antigens by a human fibroblast cell line.
Dodi AI; Brett S; Nordeng T; Sidhu S; Batchelor RJ; Lombardi G; Bakke O; Lechler RI
Eur J Immunol; 1994 Jul; 24(7):1632-9. PubMed ID: 8026524
[TBL] [Abstract][Full Text] [Related]
22. Effect of HLA-DM transfection on hen egg lysozyme presentation by T2.Ak cells.
Albert LJ; Ghumman B; Watts TH
J Immunol; 1996 Sep; 157(6):2247-55. PubMed ID: 8805621
[TBL] [Abstract][Full Text] [Related]
23. Two newly diagnosed HLA class II-deficient patients identified by rapid vector-based complementation analysis reveal discoordinate invariant chain expression levels.
Schmetterer KG; Seidel MG; Körmöczi U; Rottal A; Schwarz K; Matthes-Martin S; Steinberger P; Pickl WF
Int Arch Allergy Immunol; 2010; 152(4):390-400. PubMed ID: 20197681
[TBL] [Abstract][Full Text] [Related]
24. Highly efficient peptide binding and T cell activation by MHC class II molecules of CIITA-transfected cells.
Martinez-Soria E; Siegrist CA; Mach B
Int Immunol; 1996 Apr; 8(4):543-9. PubMed ID: 8671641
[TBL] [Abstract][Full Text] [Related]
25. Redundant proteolytic activation of a viral superantigen.
Winslow GM; Cronin T; Mix D; Reilly M
Mol Immunol; 1998 Oct; 35(14-15):897-903. PubMed ID: 9881685
[TBL] [Abstract][Full Text] [Related]
26. Regulation of the class II MHC pathway in primary human monocytes by granulocyte-macrophage colony-stimulating factor.
Hornell TM; Beresford GW; Bushey A; Boss JM; Mellins ED
J Immunol; 2003 Sep; 171(5):2374-83. PubMed ID: 12928384
[TBL] [Abstract][Full Text] [Related]
27. Astrocytes express elements of the class II endocytic pathway and process central nervous system autoantigen for presentation to encephalitogenic T cells.
Soos JM; Morrow J; Ashley TA; Szente BE; Bikoff EK; Zamvil SS
J Immunol; 1998 Dec; 161(11):5959-66. PubMed ID: 9834077
[TBL] [Abstract][Full Text] [Related]
28. Selective binding of bacterial toxins to major histocompatibility complex class II-expressing cells is controlled by invariant chain and HLA-DM.
Lavoie PM; Thibodeau J; Cloutier I; Busch R; Sékaly RP
Proc Natl Acad Sci U S A; 1997 Jun; 94(13):6892-7. PubMed ID: 9192662
[TBL] [Abstract][Full Text] [Related]
29. [Requirement of class II and membrane proximal region of mouse mammary tumor virus superantigen (Mtv SAG) in Mtv7 SAG presentation].
Okamoto M; Kimura S; Katagiri M
Hokkaido Igaku Zasshi; 1998 May; 73(3):205-14. PubMed ID: 9719947
[TBL] [Abstract][Full Text] [Related]
30. HLA-DO increases bacterial superantigen binding to human MHC molecules by inhibiting dissociation of class II-associated invariant chain peptides.
Pezeshki AM; Azar GA; Mourad W; Routy JP; Boulassel MR; Denzin LK; Thibodeau J
Hum Immunol; 2013 Oct; 74(10):1280-7. PubMed ID: 23756162
[TBL] [Abstract][Full Text] [Related]
31. HLA-DM can partially replace the invariant chain for HLA-DR transport and surface expression in transfected endocrine epithelial cells.
Serradell L; Muntasell A; Catálfamo M; Martí M; Costa M; de Préval C; Jaraquemada D
Tissue Antigens; 1999 May; 53(5):447-58. PubMed ID: 10372540
[TBL] [Abstract][Full Text] [Related]
32. MHC class II antigen presentation pathway in murine tumours: tumour evasion from immunosurveillance?
Walter W; Lingnau K; Schmitt E; Loos M; Maeurer MJ
Br J Cancer; 2000 Nov; 83(9):1192-201. PubMed ID: 11027433
[TBL] [Abstract][Full Text] [Related]
33. Herpes simplex virus type 1 targets the MHC class II processing pathway for immune evasion.
Neumann J; Eis-Hübinger AM; Koch N
J Immunol; 2003 Sep; 171(6):3075-83. PubMed ID: 12960333
[TBL] [Abstract][Full Text] [Related]
34. Cellular distribution of a mixed MHC class II heterodimer between DRalpha and a chimeric DObeta chain.
Samaan A; Thibodeau J; Mahana W; Castellino F; Cazenave PA; Kindt TJ
Int Immunol; 1999 Jan; 11(1):99-111. PubMed ID: 10050678
[TBL] [Abstract][Full Text] [Related]
35. In the absence of the invariant chain, HLA-DR molecules display a distinct array of peptides which is influenced by the presence or absence of HLA-DM.
Lightstone L; Hargreaves R; Bobek G; Peterson M; Aichinger G; Lombardi G; Lechler R
Proc Natl Acad Sci U S A; 1997 May; 94(11):5772-7. PubMed ID: 9159149
[TBL] [Abstract][Full Text] [Related]
36. Processing and major histocompatibility complex binding of the MTV7 superantigen.
Winslow GM; Marrack P; Kappler JW
Immunity; 1994 Apr; 1(1):23-33. PubMed ID: 7889395
[TBL] [Abstract][Full Text] [Related]
37. Transfer of endogenous retroviral superantigen from donor to recipient B cells following priming to induce peripheral T cell tolerance.
Modlin CS; Todd GT; Cohen TD; Fairchild RL
Cell Immunol; 1995 Sep; 164(2):217-26. PubMed ID: 7656330
[TBL] [Abstract][Full Text] [Related]
38. H2-M, a facilitator of MHC class II peptide loading, and its negative modulator H2-O are differentially expressed in response to proinflammatory cytokines.
Walter W; Scheuer C; Lingnau K; Reichert TE; Schmitt E; Loos M; Maeurer MJ
Immunogenetics; 2000 Aug; 51(10):794-804. PubMed ID: 10970094
[TBL] [Abstract][Full Text] [Related]
39. Surface-expressed invariant chain (CD74) is required for internalization of human leucocyte antigen-DR molecules to early endosomal compartments.
Moldenhauer G; Henne C; Karhausen J; Möller P
Immunology; 1999 Mar; 96(3):473-84. PubMed ID: 10233730
[TBL] [Abstract][Full Text] [Related]
40. Major histocompatibility complex class II+ invariant chain negative breast cancer cells present unique peptides that activate tumor-specific T cells from breast cancer patients.
Chornoguz O; Gapeev A; O'Neill MC; Ostrand-Rosenberg S
Mol Cell Proteomics; 2012 Nov; 11(11):1457-67. PubMed ID: 22942358
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
